{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T21:59:42Z","timestamp":1775685582652,"version":"3.50.1"},"reference-count":7,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.euo.2025.12.003","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T12:36:38Z","timestamp":1765802198000},"page":"203-204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Re: M. Roupret, A. Bertaut, G. Pignot, et al. ALBAN (GETUG-AFU 37): A Phase 3, Randomized, Open-label, International Trial of Intravenous Atezolizumab and Intravesical Bacillus Calmette\u2013Gu\u00e9rin (BCG) Versus BCG Alone in BCG-naive High-risk, Non-muscle-invasive bladder cancer (NMIBC). Ann Oncol. In press. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.017"],"prefix":"10.1016","volume":"9","author":[{"given":"David","family":"D\u2019Andrea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.12.003_b0005","doi-asserted-by":"crossref","unstructured":"Roupret M, Bertaut A, Pignot G, et al. ALBAN (GETUG-AFU 37): a phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical bacillus Calmette\u2013Gu\u00e9rin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC). Ann Oncol. In press. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.017.","DOI":"10.1016\/j.annonc.2025.09.017"},{"key":"10.1016\/j.euo.2025.12.003_b0010","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","article-title":"Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial","volume":"31","author":"Shore","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2025.12.003_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(25)01897-5","article-title":"Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial","author":"De Santis","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.12.003_b0020","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.eururo.2023.05.011","article-title":"Checkpoint inhibitors in urothelial carcinoma\u2014future directions and biomarker selection","volume":"84","author":"Meeks","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.12.003_b0025","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.euo.2025.03.007","article-title":"Oncological outcomes in bacillus Calmette-Gu\u00e9rin-na\u00efve high-risk non\u2013muscle-invasive bladder cancer patients: a systematic review on current treatment strategies and future perspectives","volume":"8","author":"Longoni","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.12.003_b0030","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.euo.2024.10.012","article-title":"Unmet need in non\u2013muscle-invasive bladder cancer failing bacillus Calmette-Gu\u00e9rin therapy: a systematic review and cost-effectiveness analyses from the International Bladder Cancer Group","volume":"8","author":"D\u2019Andrea","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.12.003_b0035","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.euo.2023.09.014","article-title":"A territory-wide study investigating the dose and efficacy of different bacillus Calmette-Guerin Strains in patients with intermediate- and high-risk non-muscle-invasive bladder cancer","volume":"7","author":"Liu","year":"2024","journal-title":"Eur Urol Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125003293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125003293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T20:57:07Z","timestamp":1775681827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125003293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2588931125003293"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.12.003","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re: M. Roupret, A. Bertaut, G. Pignot, et al. ALBAN (GETUG-AFU 37): A Phase 3, Randomized, Open-label, International Trial of Intravenous Atezolizumab and Intravesical Bacillus Calmette\u2013Gu\u00e9rin (BCG) Versus BCG Alone in BCG-naive High-risk, Non-muscle-invasive bladder cancer (NMIBC). Ann Oncol. In press. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.017","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}